ChromaCode has entered a strategic partnership with Protean BioDiagnostic for the launch of a non-small cell lung cancer (NSCLC) assay in the US.

To be available through an early access programme, the assay leverages ChromaCode’s High Definition PCR (HDPCR) multiplexing technology.

Delivering results in under 24 hours, the HDPCR NSCLC assay can help identify all National Comprehensive Cancer Network (NCCN) recommended variants in one multiplexed assay.

It has been developed for very low concentrations, needing just 15 nanograms (ng) of input DNA and 5ng of RNA.

The assay showed more than 99% coverage of target genes and a 99% concordance with next-generation sequencing, making it a better option over biomarker testing, noted ChromaCode.

Protean president and CEO Anthony Magliocco said: “We value the rapid turnaround and clinically relevant markers of the HDPCR NSCLC assay. We see a real opportunity to collaborate with commercial payors, US Department of Veterans Affairs, and other government agencies, to establish coverage and reimbursement for this revolutionary technology.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

HDPCR is an advanced approach for multiplexing biomarkers in a single, rapid assay across multiple sample types.

Implemented on ChromaCode’s cloud-based analysis platform, the HDPCR technology is suitable for use in various applications including transplant, oncology, minimal residual disease and non-invasive prenatal testing.

ChromaCode chief business officer Padma Sundar said: “This partnership aligns with our mission to increase the availability of advanced diagnostic technologies, ensuring that medical laboratories have access to cutting-edge tools that can transform the landscape of cancer care.”